Special Issue

Advances in Pathogenesis and Treatment of Colonic Diverticular Disease

Message from the Guest Editor

Diverticular disease of the colon (DDC) is a paradox. Its prevalence and the burden for patients and healthcare systems are steadily increasing, but scientific efforts need more support and intensified collaborative strategies. New insights into the genetic, molecular, and pathological background of the disease have emerged lately, but a conclusive pathogenetic model is still missing. Recommendations for treatments are changing accordingly. More insight into the pathogenesis, new targets of treatment, and more interdisciplinary discussion of controversial questions is urgently needed. The focus of Biomedicines is directed towards genetic mechanisms and molecular and pathological characteristics and their translation to medicine. Thus, a Special Issue of Biomedicines is very well adapted to foster the kind of information needed. Keywords

- colonic diverticular disease
- diverticulitis
- pathogenesis
- diagnosis
- treatment

Guest Editor

Prof. Dr. Wolfgang Kruis

Clinic for Internal Medicine and Gastroenterology, Protestant Hospital Kalk, University of Cologne, Cologne, Germany

Deadline for manuscript submissions

closed (30 June 2021)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/71150

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).